EUROMEDICA  Hanover 3-4  Juni 2010	Advanced methods of diagnosis, treatment and prophylactics
	European Academy of Natural Sciences, Hanover European Scientific Society, Hanover Berliner Medizinischen Gesellschaft, Berlin

Home

Abstracts

Contact

Disclaimer

We tested the safety of the use of Semicarbazide-Cadmium Therapy (SCT) by the Kacugin method for oncologic patients with stages 3 and 4 cancer and showed the influence of this therapy on the quality of life of these categories of patients. This investigational research therapy was given to volunteers who took standard forms of treatment without success before. The Know-How for the SCT therapy was given to us with the agreement of the holder of patent and author of the license, Dr. Leo Kacugin. In period from January 2008 till January 2010 this therapy was given to 15 patients with malignant tumors of different localizations and histological types. All patients were given SCT as a palliative therapy. The treatment was given to selected stage 3 and 4 cancer patient groups with progressive metastatic lesions.

The result of the application of this therapy showed that safety and effectiveness of SCT depends on the correct combination of all the preparations. Since this therapy has many components, use of this therapy demands a greater effort from the physician than standard chemical therapy. The optimum combination of components allows the physician to get the desired clinical effects in a couple of weeks after beginning the treatment.

In spite of well-know risks related to the action of cadmium ions on healthy cells, the use of this therapy and foundation of Know-How it represents, was to show its safety. Laboratory tests which were performed during this treatment process showed that the therapy did not have negative effects on the circulation of blood or the functions of the liver and kidneys. Analysis of the patient’s blood stayed within admissible guidelines. This means clinical side effects were not detected. In whole, the therapy stood well.

During the first day of therapy a dyspeptic phenomenon was detected in 3 patients which cut short their therapy. During the supervisory period we had stable and positive results from 8 patients. 2 patients had complete clinical and instrumental remission during 2 years, and 6 patients had remission for 6 months.

It is especially important to note that the quality of life of the patients was restored to acceptable levels. 3of the patients began work in spite of being in stage 2 disability of oncologic disease. SCT showed its effectiveness for patients in this difficult state. Other patients had a positive effect in the form of the reduction of pain syndrome and temporary lowering of expressed tumor intoxication. In our experience we can conclude that SCT meets the criteria for safety and effectiveness. Since our patients were in the final phase of the disease, the experience of using SCT shows the high effectiveness of this therapy even in these cases.

In our opinion this method should be studied by applying it not only as a palliative therapy on patients with 3-4 stages of cancer, but also for the initial stages of the oncologic process.

In our experience, SCT can be combined with such orthodox methods as the chemical therapy of tumors. However the decisions about combinations of certain medical treatments demand subsequent study.

At the present time SCT therapy is included in the spectrum of medical services which are administered at our clinic with the agreement of the owner of the patent and author of the license.